ESMO 2021 | Updates in treatments for HER2-positive GEA

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the latest developments in the treatment for HER2-positive gastroesophageal adenocarcinoma (GEA). The MAHOGANY study (NCT04082364) evaluated a chemotherapy-free regimen composed of margetuximab, a HER2-targeting monoclonal antibody, and retifanlimab, an anti-PD-1 monoclonal antibody, and showed a response rate (RR) of 53% and a progression-free survival (PFS) reaching 6.4 months. These results support further investigation for chemotherapy-free treatment options. Moreover, the INTEGA study (NCT03409848) comparing chemotherapy-free immunotherapy with trastuzumab, nivolumab, and ipilimumab with the addition of nivolumab to FOLFOX chemotherapy and trastuzumab in the first-line setting in patients with previously untreated HER2-positive locally advanced or metastatic GEA showed limited efficacy for patients treated with the chemotherapy-free regimen. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.